Instead of traditional treatment with antibiotics, bladder and urinary tract infections can be cured with cranberry capsules, without known side effects. Dutch company Medical Brands has obtained a Class IIa Medical Device Status for its patented Cranberry-Active capsule, making it the first and only cranberry-based product in Europe which has a proven medical claim.
Together with American company Decas Botanical Synergies (DBS), Medical Brands spent seven years developing the capsule and getting it patented and approved by the proper authorities.
While the claims of other cranberry-based food supplements will be rejected later this year by the European Food and Safety Authority (EFSA), Medical Brands produced studies which clinically showed that the capsule cures bladder infections. Compared to other cranberry products, MB and DBS developed a unique and proprietary formulation which is proven to treat and prevent bladder and urinary tract infections. It's the first capsule that can be freely sold as a medical device on the OTC market in all European countries.
"Bladder- and urinary tract infections (UTIs) are a serious health problem, affecting millions of people each year. Today, antibiotics are the traditional treatment for UTIs but there is a growing global push towards other solutions as resistance to antibiotics continues to rise. Our Cranberry-Active capsules marketing authorization is the culmination of years of planning, development and clinical investigation," says Maikel Hendriks, president of Medical Brands.
His company is specialised in developing medical devices without pharmacologic effects. It provides consumers with solutions for everyday diseases without the side effects most drugs have.
In the Netherlands the capsule is sold as the Bladder Infection Tablet by 'i say', in other countries Medical Brands is still searching for partners to sell the capsule. To inform potential market partners and consumers Medical Brands and DBS will present their Cranberry-Active capsules at the Vitafoods Europe 2012 conference in Geneva, Switzerland, at the Seminar Theater on Tuesday, May 22nd at 2:00 PM.